Indian institute’s unique cancer therapy goes to Malaysia
March 9th, 2010 - 10:33 am ICT by IANSBy Prashant K. Nanda
New Delhi, March 9 (IANS) After successfully treating hundreds of cancer patients in India, a Noida-based institute has now accepted an offer from Malaysia to provide targeted “dendritic cell” therapy to patients there.
The Institute of Cellular Therapies (ICT) has devised a new treatment that uses cell-based cancer immuno-therapy - treatment using the patient’s own mononuclear cells transformed into cancer-specific dendritic (immune system regulatory) cells.
Through this therapy, medical experts extract the mononuclear (CD14+) cells from the patient’s own blood, transform these cells into cancer-fighting cells and implant them back in the patients body.
“Dendritic cell therapy is a targeted add-on treatment for cancer patients. It helps the recovery process and reduces the chance of relapse of the disease among patients. We are happy that the Malaysian government authorities now want this treatment to be made available there,” senior doctor and ICT director Jamal A. Khan told IANS.
Khan said that his institute will set up a cell culture lab for clinical trials in Malaysia very soon.
He said ICT will work in tandem with Malaysia’s health ministry to set up the lab and making this treatment popular. Malaysia is currently importing the medicine from ICT and after the lab comes up in the country, ICT will manufacture the medicine - Denvax - in Malaysia.
“This treatment is not available in Malaysia and it will work as an additional facility for the people of that country. Our therapy targets the cancer cells without affecting other cells around the cancerous part of the body,” he added.
Khan said Denvax targets only the cancer cells without harming the healthy ones. It is safe and effective and works best to prevent relapse and recurrences, the major cause of mortality and morbidity.
Denvax helps in correcting the failed immune surveillance and teaches the immune system to recognize and kill cancer cells.
“Denvax destroys the disseminated cancer cells, thereby preventing its development, slowing the spread of cancer and improving life expectancy,” the senior doctor added.
(Prashant K. Nanda can be contacted at prashant.n@ians.in)
- How reovirus kills cancer cells - Feb 21, 2011
- Scientists develop new method to produce natural killer cells for cancer - Jun 11, 2010
- New probiotic fights inflammatory bowel diseases - Feb 01, 2011
- New study shows evidence of stem cells' pivotal role in cancer - Dec 22, 2010
- Life work culminates in testing of cancer therapy in humans - Mar 24, 2011
- How breast cancer cells dodge immune system and survive - Feb 02, 2011
- New genetic signatures of breast cancer drug resistance identified - Jan 11, 2011
- Melanoma-initiating cell identified - Jul 01, 2010
- Scientists use patient's tumor to form cancer vaccine - Nov 25, 2010
- Surgery effective for aggressive prostate cancer patients - Sep 28, 2010
- New cell therapy shows promise against atherosclerosis - Mar 02, 2011
- Discovery could lead to 'next-gen' vaccines - Apr 08, 2012
- New discovery shows promise against non-small cell lung cancer - Dec 04, 2010
- Intestinal stem cells offer clues to colon cancer origin and relapse - Mar 18, 2011
- Gene mutations help leukemia drug fight squamous cell lung cancer - Apr 04, 2011
Tags: cancer cells, cancer patients, cancer therapy, cell culture lab, cellular therapies, clinical trials, dendritic cell therapy, government authorities, health ministry, immune surveillance, immune system, malaysian government, medical experts, mononuclear cells, mortality and morbidity, nanda, New Delhi, prashant, regulatory cells, relapse